KSHV-RBPome
Financiado
Elucidating the role of RNA-binding proteins in Kaposi’s sarcoma-associated herp...
Elucidating the role of RNA-binding proteins in Kaposi’s sarcoma-associated herpesvirus infected cells during latency-reactivation switches
Kaposi’s sarcoma-associated herpesvirus (KSHV), an oncogenic human γ-herpesvirus, is the cause of Kaposi’s Sarcoma (KS), primary effusion lymphoma and multicentric Castleman's disease with no effective therapies. Like other herpes...
Kaposi’s sarcoma-associated herpesvirus (KSHV), an oncogenic human γ-herpesvirus, is the cause of Kaposi’s Sarcoma (KS), primary effusion lymphoma and multicentric Castleman's disease with no effective therapies. Like other herpesviruses, KSHV has a latent cycle with limited gene expression and a lytic cycle with expression of most viral genes and production of infectious viral particles. RNA-binding proteins (RBP) play key roles in RNA biology, including expression, export, stability, processing and translation. Previous reports showed that RBPs can function as proviral or antiviral. Viruses also express viral RBPs. There are no reports investigating the role of RBPs during infection with DNA viruses. Here we aim to determine the scope of host and viral RBPs involved in KSHV latent infection and reactivation. To do so, we will employ a multidisciplinary approach that combines cutting edge methods of molecular biology and virology with next generation technologies to discover cellular RBPs that directly interact with viral RNA and regulate KSHV infection and tumorigenesis. We expect also to discover novel viral RBPs involved in KSHV infection and pathogenesis. The outcome of this project will be a comprehensive census of RBPs with antiviral, proviral and pro-oncogenic activities. In the short-term, the knowledge obtained will facilitate the development of biotechnological applications to exploit the function of RBPs in RNA biology, including RNA visualization, expression and translation. In the long-term, the proviral RBPs could be targeted to develop host-based antivirals. Therefore, this project contributes to the EU global challenge of Health and the EU Mission Cancer. To ensure the successful outcome of this project, I will contribute with my experience in molecular virology and my supervisors will train me in system-wide profiling of RBPs and cutting-edge methods in virology, ensuring the appropriate transfer of knowledge among the participants.
ver más
Duración del proyecto: 35 meses
Fecha Inicio: 2023-08-02
Fecha Fin: 2026-07-31
Fecha Fin: 2026-07-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-08-02
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2022-PF-01-01:
MSCA Postdoctoral Fellowships 2022
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
190K€
Líder del proyecto
MEDIZINISCHE HOCHSCHULE HANNOVER
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
N.D. |
Participante